Valbenazine as treatment for Huntington's disease chorea

Affiliations

¹ Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
² Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria. Electronic address: klaus.seppi@i-med.ac.at.

Comment

Beatrice Heim et al. Lancet Neurol. 2023 Jun.

. 2023 Jun;22(6):459-460.

doi: 10.1016/S1474-4422(23)00163-1.

¹ Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
² Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria. Electronic address: klaus.seppi@i-med.ac.at.

No abstract available

Comment on

Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D; Huntington Study Group KINECT-HD Collaborators. Furr Stimming E, et al. Lancet Neurol. 2023 Jun;22(6):494-504. doi: 10.1016/S1474-4422(23)00127-8. Lancet Neurol. 2023. PMID: 37210099 Clinical Trial.